6hon MSN
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market
On Wednesday, Ionis Pharmaceuticals Inc. IONS said it is cutting the annual list price of its triglyceride-lowering drug Tryngolza (olezarsen) to $40,000 from $595,000. The move positions the therapy ...
Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...
Zacks Investment Research on MSN
FDA grants priority tag to Ionis' NDA for Alexander disease drug
Ionis Pharmaceuticals IONS announced that the FDA has granted priority review to its new drug application (NDA) seeking ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Thursday approved ...
Ionis Pharma projects $2B+ peak revenue for Olezarsen, which is highly conservative given the U.S. addressable market. Read ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic ...
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ...
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results